CClinicalTrials.gg
CompletedNCT07836686Updated Sep 23, 2026

Clinical and Radiographic Success of Modified LSTR Techniques in Primary Second Molars

An interventional study of 3Mix-MP Antibiotic Paste and 3Mix-NS Antibiotic Paste in Pulp Necrosis and Irreversible Pulpitis, sponsored by Uşak University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 4 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Uşak University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Non-randomized
Ages
4 Years to 11 Years
Sex
All
01

Study summary

This study aimed to evaluate and compare the clinical and radiographic success of different antibiotic and vehicle modifications of the Lesion Sterilization and Tissue Repair (LSTR) technique in infected mandibular primary second molars. The study included systemically healthy children aged 4-11 years. Participants were assigned to four treatment groups according to the antibiotic combination (3Mix or 2Mix) and vehicle used [Macrogol-Propylene Glycol (MP) or normal saline (NS)]: 3Mix-MP, 3Mix-NS, 2Mix-MP, and 2Mix-NS. Clinical outcomes were evaluated at 3, 6, and 12 months after treatment, and radiographic outcomes were evaluated at 6 and 12 months. The clinical and radiographic success of the four LSTR modifications was compared over the 12-month follow-up period.

Read the detailed description

This study was conducted to evaluate and compare the clinical and radiographic success of different antibiotic and vehicle modifications of the Lesion Sterilization and Tissue Repair (LSTR) technique in infected mandibular primary second molars.

A total of 64 systemically healthy children aged 4-11 years were included in the study. The cases were assigned to four treatment groups according to the antibiotic combination (3Mix or 2Mix) and the vehicle used [Macrogol-Propylene Glycol (MP) or Normal saline (NS)]. The four treatment groups were 3Mix-MP, 3Mix-NS, 2Mix-MP, and 2Mix-NS.

Following LSTR treatment, clinical evaluations were performed at 3, 6, and 12 months, while radiographic evaluations were performed at 6 and 12 months. Clinical and radiographic findings were assessed at the specified follow-up periods to determine treatment success and to compare the outcomes of the four LSTR modifications over a 12-month follow-up period.

02

Conditions studied

  • Pulp Necrosis
  • Irreversible Pulpitis

Browse trials for

Keywords

  • Double Antibiotic Paste
  • LSTR
  • Primary Molar Teeth
  • Triple Antibiotic Paste
03

Who can participate

Ages eligible
4 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Children aged 4-11 years. Systemically healthy children. Presence of deep caries, pulp necrosis, or irreversible pulpitis in a mandibular primary second molar indicated for LSTR treatment.

Patients unsuitable for conventional pulpectomy due to poor cooperation. At least 6 months remaining before physiological exfoliation of the affected tooth.

Root resorption not exceeding one-third of the root length. No furcation perforation. Furcation radiolucency not extending to the permanent tooth germ. Sufficient remaining tooth structure for restoration. Parent/legal guardian willing to provide informed consent.

Exclusion criteria

Exclusion Criteria:

  • Risk of infective endocarditis. Known allergy to any antibiotic used in the study. Root resorption exceeding one-third of the root length. Extensive furcation involvement extending toward the permanent tooth germ. Insufficient remaining tooth structure for restoration. Parent/legal guardian declining informed consent.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    3Mix-MP

    Participants in this arm received LSTR treatment using the 3Mix antibiotic combination with Macrogol-Propylene Glycol (MP) as the vehicle.

    Drug: 3Mix-MP Antibiotic Paste

  • Experimental
    3Mix-NS

    Participants in this arm received LSTR treatment using the 3Mix antibiotic combination with normal saline (NS) as the vehicle.

    Drug: 3Mix-NS Antibiotic Paste

  • Experimental
    2Mix-MP

    Participants in this arm received LSTR treatment using the 2Mix antibiotic combination with Macrogol-Propylene Glycol (MP) as the vehicle.

    Drug: 2Mix-MP Antibiotic Paste

  • Experimental
    2Mix-NS

    Participants in this arm received LSTR treatment using the 2Mix antibiotic combination with normal saline (NS) as the vehicle.

    Drug: 2Mix-NS Antibiotic Paste

Interventions

  • Drug3Mix-MP Antibiotic Paste

    The 3Mix antibiotic powder consisted of metronidazole, ciprofloxacin, and clindamycin mixed in a 1:1:1 ratio. Macrogol and propylene glycol were mixed in a 1:1 ratio to prepare the vehicle. Immediately before application, the antibiotic powder and the vehicle were combined at a 7:1 ratio to form a homogeneous paste, which was used as part of the LSTR treatment.

  • Drug3Mix-NS Antibiotic Paste

    The 3Mix antibiotic powder consisted of metronidazole, ciprofloxacin, and clindamycin mixed in a 1:1:1 ratio. Normal saline (NS) was used as the vehicle. Immediately before application, the antibiotic powder and normal saline were combined at a 7:1 ratio to form a homogeneous paste, which was used as part of the LSTR treatment.

  • Drug2Mix-MP Antibiotic Paste

    The 2Mix antibiotic powder consisted of metronidazole and ciprofloxacin mixed in a 1:1 ratio. Macrogol and propylene glycol were mixed in a 1:1 ratio to prepare the vehicle. Immediately before application, the antibiotic powder and the vehicle were combined at a 7:1 ratio to form a homogeneous paste, which was used as part of the LSTR treatment.

  • Drug2Mix-NS Antibiotic Paste

    The 2Mix antibiotic powder consisted of metronidazole and ciprofloxacin mixed in a 1:1 ratio. Normal saline (NS) was used as the vehicle. Immediately before application, the antibiotic powder and normal saline were combined at a 7:1 ratio to form a homogeneous paste, which was used as part of the LSTR treatment.

05

What researchers measure

Primary outcomes

  1. Clinical Success of LSTR Treatment

    Clinical success was defined as the absence of pain or tenderness, swelling or fistula, pathological mobility, and tenderness to percussion. The presence of any of these signs or symptoms was considered clinical failure

    Time frame: 3, 6, and 12 months after treatment

  2. Radiographic Success of LSTR Treatment

    Radiographic success was defined as stabilization, reduction, or complete resolution of existing interradicular and periradicular radiolucency, with no development of new radiographic lesions. Failure to meet any of these criteria was considered radiographic failure.

    Time frame: 6 and 12 months after treatment

  3. Overall Success of LSTR Treatment

    Overall treatment success was defined as fulfillment of both the clinical and radiographic success criteria. A case was considered unsuccessful if either the clinical or radiographic success criteria were not met.

    Time frame: 6 and 12 months after treatment

06

Study locations

1 site
  • Uşak University Faculty of Dentistry
    Uşak, Uşak, Turkey (Türkiye)
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07836686
Lead sponsor
Uşak University
Responsible party
Sponsor
First posted
Sep 23, 2026
Start date
Nov 26, 2024
Primary completion
Mar 5, 2026
Completion
Mar 5, 2026
Last update
Sep 23, 2026

Study contacts

Merve ALKIŞ, DDS
study director · Usak Universty
Merve AKAR, DDS
principal investigator · Usak Universty

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion